SubscribeElsewhere on HealthThreads: Stomach cancer | Lymphoma | Overactive bladder | Thyroid cancer |
US FDA grants fast track designation for apaziquone for bladder cancer 
PharmaBiz | Thu, Jul 23
PharmaBiz is the #11 Blogger for Bladder cancer
Spectrum Pharmaceuticals and Allergan, Inc announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of apaziquone (EOquin) for the treatment of non-muscle invasive bladder cancer, a form of bladder cancer localized in the su...
Try These Related Topics
More PharmaBiz
Related News
The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive ...
Rosetta Genomics Reports Third Quarter Financial Results, Provides Business Update
Postoperative nomogram for invasive bladder cancer: Does it really work? A ...
Comparing the safety and efficiency of conventional monopolar, plasmakinetic ...
Sonic hedgehog pathway variations could be linked to non-invasive bladder cancer
Sonic Hedgehog Variations Linked to Recurrence, Survival and Response to ... - Science Daily
Top Bloggers
Related Photos
Opinion: Indevus Pharmaceuticals: Valstar reintroduced into bladder cancer ...
SYS-CON Media (press release) There is a high unmet need in the treatment of recurrent CIS bladder tumors because, generally, they do not respond well to chemotherapy. BCG immunotherapy shows the best efficacy against recurrent CIS bladder tumors, but patients often show poor ...
Thu, Mar 19 | from drugdiscovery.pharmaceutical-business-review.com
